INSPIRE, trial summary

A randomised clinical trial investigating the effect of versus in

NCT00982111    Lancet Oncol 2015;16:328-37  




Studied treatment
Control treatment



Patients
Group sizes -9 / -9



Blindness Inclusion period
Follow-up duration Centers
Lost to FU geographical localisation
Primary endpoint Design



EndpointX1N1X0N0TE95% CI0,22,01,0


Paz-Ares L, Mezger J, Ciuleanu TE, Fischer JR, von Pawel J, Provencio M, Kazarnowicz A, Losonczy G, de Castro G Jr, Szczesna A, Crino L, Reck M, Ramla Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. Lancet Oncol 2015;16:328-37     [PMID: 25701171]   link to pdf  



Registering number NCT00982111 (see trial on clinicaltrials.gov)
Code Name

 




Appears in following systematic reviews: